John Farah
Director/Board Member chez AEOLUS PHARMACEUTICALS, INC.
Fortune : 1 339 $ au 31/03/2024
Profil
John Mitchell Farah is an Independent Director at Aeolus Pharmaceuticals, Inc. since 2011.
He is also a Director at Pond Technologies Holdings, Inc. since 2021.
Previously, he served as an Independent Director at Rebus Holdings, Inc. from 2008 to 2010.
He was the VP-International Pharmaceutical Operations at Cephalon, Inc. from 1992 to 2011.
He also held positions at Melior Discovery, Inc. as Chief Business Officer and at G.D.
Searle & Co., Inc. as a Discovery Research Scientist.
Dr. Farah completed his undergraduate studies at New College of California and the University of Maryland.
He obtained a doctorate degree from the Uniformed Services University of the Health Sciences in 1985.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2024 | 63 782 ( 0,09% ) | 1 339 $ | 31/03/2024 |
Postes actifs de John Farah
| Sociétés | Poste | Début |
|---|---|---|
| AEOLUS PHARMACEUTICALS, INC. | Director/Board Member | 24/10/2005 |
| POND TECHNOLOGIES HOLDINGS INC. | Director/Board Member | 14/07/2021 |
Anciens postes connus de John Farah
| Sociétés | Poste | Fin |
|---|---|---|
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Corporate Officer/Principal | - |
| REBUS HOLDINGS, INC. | Director/Board Member | 17/08/2010 |
Melior Discovery, Inc.
 Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Director/Board Member | 16/01/2013 |
G.D. Searle & Co., Inc.
 G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Chief Tech/Sci/R&D Officer | - |
Formation de John Farah
| New College of California | Undergraduate Degree |
| University of Maryland | Undergraduate Degree |
| Uniformed Services University of the Health Sciences | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| REBUS HOLDINGS, INC. | Health Technology |
| AEOLUS PHARMACEUTICALS, INC. | Health Technology |
| POND TECHNOLOGIES HOLDINGS INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
Melior Discovery, Inc.
Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Commercial Services |
G.D. Searle & Co., Inc.
G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Process Industries |
